Mobile Lithotripsy Services · UK public procurement notice

CPV: Urologist services

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Unspecified in notice

Recurring procurement

Unspecified in notice

First published

20 May 2026, 15:26 BST

Last source update

20 May 2026, 15:26 BST

Authority reference

CAV-DAP2 (26-27) 18

FTS notice number

2026/S 000-046529

Classification (CPV)

Urologist services

Delivery area

Wales (UKL22)

Official registry OCID

ocds-h6vhtk-069dc8 Find a Tender

Why no open competition

New works/services, constituting a repetition of existing works/services and ordered in accordance with the strict conditions stated in the directive

Published justification

This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority by 03/06/2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales.

Publisher note: This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 02/06/2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales. Providers should send their written representation during the standstill period to Sam.Davies8@wales.nhs.uk The Cardiff and Vale University Health Board intends to utilise Direct Award Process 2 under the Provider Selection Regime (Wales) to award a contract for the provision of Mobile Lithotripsy Services to the incumbent provider. - No providers were excluded from this Procurement - There were no declared conflicts of individuals making the decision - There is no information withheld under regulation 23 (1) 1. Applicability of Direct Award Process 2 Direct Award Process 2 is considered appropriate where: · The existing provider is delivering services to an acceptable standard, and · Changing provider would likely result in disruption, reduced quality, or disproportionate costs/risk, and · The service is of a nature where continuity and integration are critical to patient outcomes. The current service provided by the incumbent provider meets these criteria. 2. Performance of Current Provider The incumbent provider has: · Consistently delivered safe, high-quality lithotripsy services in line with clinical requirements · Demonstrated strong clinical outcomes and patient satisfaction · Maintained compliance with all contractual KPIs and governance standards · Established effective clinical integration with Urology, Radiology, and surgical teams. There are no significant performance concerns that would justify market testing at this time. 3. Continuity of Care and Clinical Integration Mobile Lithotripsy is a highly specialised, pathway critical service, requiring: · Integration with pre and post procedure diagnostic pathways · Coordination with theatre scheduling, imaging, and urology clinics · Established clinical protocols and multidisciplinary working A change in provider would introduce: · Risk of service disruption and delays in treatment · Loss of embedded processes and clinical familiarity · Potential impact on waiting time performance and patient outcomes Maintaining the current provider supports continuity of care and pathway stability. 4. Technical and Operational Considerations The incumbent provider: · Supplies specialist mobile equipment aligned with site infrastructure · Provides experienced clinical and technical staff familiar with local systems · Has established operational logistics for mobile unit deployment Transitioning to a new provider would require: · Equipment validation and compatibility checks · Staff onboarding and training · Reconfiguration of operational pathways This would result in avoidable cost, delay, and operational risk. 5. Value for Money The current arrangement: · Provides demonstratable value for money · Avoids mobilisation costs associated with a new provider · Minimises inefficiencies during transaction period A competitive process is unlikely to delivery significantly improved value when factoring in transition risks and costs. 6. Patient Impact Maintaining the current provider supports: · Timely access to treatment, reducing waiting list pressures · Continuity in patient experience and clinical outcomes · Minimisation of clinical risk associated with change (WA Ref:164966)

• Focus Medical Services LtdAwarded supplier Buckland House 2, Park 5, Exeter, UK, EX27HU

No document links were published on the notice.